All In Biotech

Drug Trial Radar · NCT02961829

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Last checked: Nov 20, 2026Latest source record: Jul 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jul 2015

Primary completion

Mar 2019

Study completion Mar 2020

Sponsor

Lead sponsor
Federal University of São PauloAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de Desenvolvimento Científico e Tecnológico; ViiV Healthcare
First posted
Nov 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is becoming clear that a combination of interventions will be desirable to achieve HIV cure. Therefore the investigators propose a pilot proof of concept study, using combination of a number of different interventions for eradicating residual plasma viremia and decreasing HIV reservoirs. The investigators hypothesize that, (i) antiretroviral intensification using Maraviroc, and/or dolutegravir with (ii) Dendritic Cell vaccination using autologous HIV, and (iii) purging intervention using the Class III HDACs, Sirtuin-1, and (iv) decreasing the ratio of long-lived central memory (TCM)/transitional memory (TTM) CD4+ T-cells using Auranofin will provide a synergistic impact leading to a sterilizing cure of HIV infection. Results of this study may provide insightful evidence for planning the next steps using the more efficacious combination of intervention strategies towards HIV sterilizing cure.

Conditions

  • Chronic Infection
  • HIV

Interventions

  • MaravirocDrug

    antiretroviral intensification

  • DolutegravirDrug

    antiretroviral intensification

  • Dendritic Cell VaccineBiological

    Therapeutic vaccination

  • AuranofinDrug

    purging

  • Sirtuin Histone deacetylase inhibitorDrug

    latency disruption

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ultrasensitive RNA Viral load,Time frame: from baseline and every 4 weeks up to 48 weeks.
  2. Cell-associated HIV RNATime frame: from baseline and every 4 weeks up to 48 weeks.
  3. Episomal DNATime frame: from baseline and every 4 weeks up to 48 weeks
  4. specific HIV antibodiesTime frame: from baseline and every 4 weeks up to 48 weeks
  5. CD38 and HLA-DR on CD4 and CD8+ cellsTime frame: from baseline and every 4 weeks up to 48 weeks
  6. PBMC for env sequence evolutionTime frame: from baseline and every 4 weeks up to 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CCDI

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.